Skip to main content
HLN logo

Haleon plc (HLN) Stock Price & Analysis

Haleon plc (HLN) — MoonshotScore 75/100 (Strong band), calculated Nov 18, 2026. Price $9.08 (+0.33%), as of the Nov 18, 2026 trading session; market cap $39.8B.

Educational signal · not a buy or sell recommendation · How to read this

$9.08 +$0.03 (+0.33%) Market Cap $39.8B

Haleon plc · HLN · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods.

Price as of Nov 18, 2026

Key Statistics

75 of 100

MoonshotScore v2 · Haleon (HLN)

Strong
Business Quality Elite (83)
Financial Safety Okay (46)
Valuation Fair (63)
Growth Durability Growing (75)
Momentum Rising (72)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and durable growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.

  • quarterly revenue £5.64B (Q2 FY2026, quarter ended Jun 30, 2026)
  • Altman Z 2.85 · Piotroski F 8
  • ROE 9.9% · ROA 5.0% · current ratio 0.69 · earnings yield 5.2% · free-cash-flow yield 3.9%

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for HLN (52 recorded, newest six shown)
RecordedScoreBand
75Strong
75Strong
75Strong
75Strong
75Strong
75Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$9.08
Change on the day+0.33%
52-week range$8.38–$11.28
Market capitalisation$39.8B—
Price / earnings (trailing)18.87
Shares traded on the day19.46M
Beta (volatility vs the S&P 500)0.25

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $8.66, high $11, latest $9.08. $11 $8.66 high $11 Oct 17, 2025 Nov 18, 2026 · $9.08 $9.48Oct 17, 2025$9.27Oct 31, 2025$9.59Nov 14, 2025$9.78Nov 28, 2025$9.52Dec 12, 2025$10Dec 26, 2025$9.91Jan 9, 2026$10Jan 23, 2026$11Feb 6, 2026$11Feb 20, 2026$10Mar 6, 2026$10Mar 20, 2026$9.93Apr 2, 2026$9.75Apr 17, 2026$9.38May 1, 2026$8.96May 15, 2026$9.06May 29, 2026$9.13Jun 12, 2026$9.24Jun 26, 2026$9.76Jul 10, 2026$9.78Jul 24, 2026$10Aug 7, 2026$10Aug 21, 2026$9.60Sep 4, 2026$9.28Sep 18, 2026$8.80Oct 2, 2026$10Oct 16, 2026$8.66Oct 30, 2026$9.17Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Haleon (HLN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Moderate
Momentum Moderate

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Debt/Equity Neutral
ROE Neutral
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Haleon (HLN), and what does it report?

Short answer

Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. Haleon plc (HLN) is listed on NYSE. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: Building 5, First Floor, THE Heights, Weybridge, X0, KT13 0NY. It employs 24,535 people and is led by Brian James McNamara. In Q2 FY2026 it reported revenue of £5.64B and net income of £768M. The market values it at $39.8B.

2 · Latest results

What do the latest results show for Haleon (HLN)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of £5.64B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026£5.64B£768M£0.17 (diluted)
Q4 FY2025£5.52B£856M£0.19 (diluted)
Q2 FY2025£5.48B£806M£0.18 (diluted)
Q1 FY2025£2.74B£403M£0.09 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Haleon (HLN)?

Short answer · as of

The MoonshotScore pillars rate business quality, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 2.85 · Piotroski F 8. Trailing ratios: ROE 9.9% · ROA 5.0% · current ratio 0.69 · earnings yield 5.2% · free-cash-flow yield 3.9%.

5 · Peer comparison

How does Haleon compare with its peers?

Short answer

Haleon's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Lantheus Holdings, Inc. (LNTH) Same industry, near in market value$102.00 Nov 18, 2026$6.67B96 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Named competitor$272.37 Nov 19, 2026$63.0B88 5-pillar Nov 18, 2026
Zoetis Inc. (ZTS) Same industry, near in market value$85.57 Nov 18, 2026$34.8B87 5-pillar Nov 18, 2026
Agilent Technologies, Inc. (A) Named competitor$177.33 Nov 18, 2026$50.0B83 5-pillar Nov 18, 2026
Humana Inc. (HUM) Named competitor$385.78 Nov 18, 2026$46.3B79 5-pillar Nov 18, 2026
Dr. Reddy's Laboratories Limited (RDY) Same industry, near in market value$14.85 Nov 19, 2026$12.4B77 5-pillar Nov 18, 2026
Haleon (HLN) — this page$9.08$39.8B75
Supernus Pharmaceuticals, Inc. (SUPN) Same industry, near in market value$28.96 Nov 18, 2026$6.02B74 5-pillar Nov 18, 2026
Takeda Pharmaceutical Company Limited (TAK) Named competitor$21.27 Nov 18, 2026$68.0B73 5-pillar Nov 18, 2026
HUTCHMED (China) Limited (HCM) Same industry, near in market value$13.99 Nov 18, 2026$2.43B70 5-pillar Nov 18, 2026
Becton, Dickinson and Company (BDX) Named competitor$212.73 Nov 19, 2026$57.9B68 5-pillar Nov 18, 2026
Amneal Pharmaceuticals, Inc. (AMRX) Same industry, near in market value$21.88 Nov 18, 2026$7.62B66 5-pillar Nov 18, 2026
Teva Pharmaceutical Industries Limited (TEVA) Same industry, near in market value$42.23 Nov 18, 2026$49.3B57 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held HLN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported HLN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Haleon (HLN)?

Read these with our analysis →

HLN Healthcare Stock FAQ

These answers are editorial: 1 of these 9 answers is drawn from the HLN research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for HLN?

HLN carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Haleon plc (HLN) is a leading consumer healthcare company focused on the research, development, and sale of over-the-counter products.

Is HLN a good stock to buy?

Stock Expert AI does not rate HLN buy, sell or hold. Haleon plc carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the HLN stock price today?

The last price recorded for Haleon plc (HLN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for HLN?

Haleon plc faces several risks, including regulatory hurdles that could delay product approvals, impacting its ability to launch new products.

What are the key factors to evaluate for HLN?

Haleon plc (HLN) holds a MoonshotScore in the high range. To weigh it, start with the trailing P/E under Price & valuation on this page. Haleon's established brand presence and distribution networks will enable it to capture a larger market share in these regions over the next five years. Not financial advice.

How frequently does HLN data refresh on this page?

HLN's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven HLN's recent stock price performance?

Haleon plc (HLN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand portfolio with high consumer recognition. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider HLN overvalued or undervalued right now?

The trailing P/E of Haleon plc (HLN) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research HLN before investing?

Before investing in Haleon plc (HLN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 1 from SEC filings and earnings calls, 14 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold HLN

Funds in our ETF coverage that list HLN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
GMO International Quality ETF (QLTI)4.00%